Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway - and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.
More from STAT:
Become a subscriber: www.statnews.com/stat-plus/
Watch Full Episodes: / @statnews
Newsletters: www.statnews.com/signup/
STAT events: www.statnews.com/stat-events/
Facebook: / statnews
Twitter: / statnews
Instagram: / statnews
Flipboard: rb.gy/3xnsxr
STAT Reports: rb.gy/rexfwj
STAT eBooks: rb.gy/eme3h5
ABOUT STAT:
Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry - and a revolution in human health.